In our study, AChR-MG and MuSK-MG patients did not show statistically significant differences in achieving therapeutic goals and oral GC doses; however, MuSK-MG was significantly less likely to reach therapeutic goals than AChR-MG. Here, MUSK is linked to myasthenia gravis.